Definitive treatment patterns and survival in stage II non-small cell lung cancer

被引:3
|
作者
Yan, Sherry X. [1 ]
Qureshi, Muhammad M. [2 ,3 ]
Suzuki, Kei [3 ,4 ]
Dyer, Michael [2 ,3 ]
Truong, Minh Tam [2 ,3 ]
Litle, Virginia [3 ,4 ]
Mak, Kimberley S. [2 ,3 ]
机构
[1] Boston Med Ctr, One Boston Med Ctr Pl, Boston, MA 02118 USA
[2] Boston Med Ctr, Dept Radiat Oncol, 830 Harrison Ave, Boston, MA 02118 USA
[3] Boston Univ, Sch Med, 72 E Concord St, Boston, MA 02118 USA
[4] Boston Med Ctr, Dept Surg, Div Thorac Surg, 830 Harrison Ave,3rd Floor, Boston, MA 02118 USA
关键词
Non-small cell lung cancer; Treatment patterns; Survival; Surgery; Radiotherapy; BODY RADIATION-THERAPY; PHASE-III; TNM CLASSIFICATION; UNITED-STATES; FRACTIONATED RADIOTHERAPY; TRIAL; CONCURRENT; MANAGEMENT; PROPOSALS; GROUPINGS;
D O I
10.1016/j.lungcan.2018.07.035
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: This study delineated definitive treatment patterns for Stage II non-small cell lung cancer (NSCLC) in the United States and evaluated survival by treatment approach. Materials and Methods: Patients with clinically-staged Stage II NSCLC treated with surgery-based therapy, chemoradiation, conventionally-fractionated radiation (CFR), or stereotactic body radiotherapy (SBRT) were identified using the National Cancer Database (NCDB). Median survival was estimated using Kaplan-Meier analysis. Crude and adjusted hazard ratios (HR) and 95% confidence intervals were computed using Cox regression modeling. Results: Between 2004-2012, 19,749 patients met study criteria: 13,382 (67.8%) underwent surgery-based treatment, 4,310 (21.8%) received chemoradiation, 1,606 (8.1%) received CFR, and 451 (2.3%) received SBRT. Surgery and SBRT utilization increased over time while CFR and chemoradiation decreased (all p < 0.002). Patients receiving radiation-based treatments were older, with more comorbidities, and higher T/N stage (all p < 0.0001). With median follow-up of 25.2 months, median survival was 51.6, 23.3, 15.4, and 23.7 months for surgery-based treatment, chemoradiation, CFR, and SBRT, respectively (p < 0.0001). On multivariate analysis, chemoradiation (HR 1.67 [1.59-1.75], p < 0.0001), CFR (HR 2.38 [2.22-2.55], p < 0.0001), and SBRT (HR 1.76 [1.53-2.01], p < 0.0001) were associated with decreased survival versus surgery-based treatment. CFR was associated with decreased survival versus chemoradiation (HR 1.52 [1.41-1.63], p < 0.0001) and SBRT (HR 1.39 [1.19-1.61], p < 0.0001). SBRT was associated with similar survival versus chemoradiation (HR 1.10 [0.95-1.27], p = 0.212). Conclusion: NCDB data demonstrate increasing use of surgery-based treatments and SBRT for Stage II NSCLC over time. Radiation-based therapies were associated with decreased survival compared to surgery. CFR was associated with decreased survival compared to chemoradiation and SBRT.
引用
收藏
页码:135 / 142
页数:8
相关论文
共 50 条
  • [21] Survival in untreated early stage non-small cell lung cancer
    Chadha, AS
    Ganti, AK
    Sohi, JS
    Sahmoun, AE
    Mehd, SA
    ANTICANCER RESEARCH, 2005, 25 (05) : 3517 - 3520
  • [22] Extending Survival of Stage IV Non-Small Cell Lung Cancer
    Carnio, Simona
    Novello, Silvia
    Mele, Teresa
    Levra, Matteo Giaj
    Scagliotti, Giorgio Vittorio
    SEMINARS IN ONCOLOGY, 2014, 41 (01) : 69 - 92
  • [23] Is survival improving in stage IV non-small cell lung cancer?
    Birnbaum, A. E.
    Ng, T.
    O'Connor, B.
    Plette, A.
    Berz, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] Predictors for pneumonitis for stage II-III non-small cell lung cancer after definitive radiotherapy
    Xu, Xiaohong
    He, Jian
    RADIOTHERAPY AND ONCOLOGY, 2024, 197 : S212 - S213
  • [25] Therapy for stage I and stage II non-small cell lung cancer
    Tanoue, LT
    Ponn, RB
    CLINICS IN CHEST MEDICINE, 2002, 23 (01) : 173 - +
  • [26] TREATMENT PATTERNS IN NON-SMALL CELL LUNG CANCER IN FRANCE
    Klein, A. B.
    Wang, H.
    Shire, N.
    Chalubert, H.
    Alessandrini, E. R.
    Descoins, S.
    Medina, P.
    VALUE IN HEALTH, 2017, 20 (09) : A418 - A418
  • [27] Clinical patterns and treatment outcome of elderly patients in clinical stage IB/II non-small cell lung cancer
    Okamoto, T
    Maruyama, R
    Shoji, F
    Ikeda, J
    Miyamoto, T
    Nakamura, T
    Asoh, H
    Ichinose, Y
    JOURNAL OF SURGICAL ONCOLOGY, 2004, 87 (03) : 134 - 138
  • [28] Social factors, treatment, and survival in early-stage non-small cell lung cancer
    Greenwald, HP
    Polissar, NL
    Borgatta, EF
    McCorkle, R
    Goodman, G
    AMERICAN JOURNAL OF PUBLIC HEALTH, 1998, 88 (11) : 1681 - 1684
  • [29] Impact of Multimodality Treatment Sequence on Survival in Stage IIB Non-Small Cell Lung Cancer
    Stokes, Sean M.
    Massarweh, Nader N.
    Stringham, John R.
    Varghese, Thomas K.
    ANNALS OF THORACIC SURGERY, 2021, 112 (05): : 1559 - 1567
  • [30] Resection in Stage I/II Non-Small Cell Lung Cancer
    Smolle-Juettner, F. M.
    Maier, A.
    Lindenmann, J.
    Matzi, V.
    Neuboeck, N.
    CONTROVERSIES IN TREATMENT OF LUNG CANCER, 2010, 42 : 71 - 77